These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Treatment of Parkinson's disease : what's on the horizon? Wu SS; Frucht SJ CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989 [TBL] [Abstract][Full Text] [Related]
8. Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies. Ciceri F; Rotllant D; Maes T Curr Pharm Des; 2017; 23(5):839-857. PubMed ID: 28120717 [TBL] [Abstract][Full Text] [Related]
9. Old and new challenges in Parkinson's disease therapeutics. Pires AO; Teixeira FG; Mendes-Pinheiro B; Serra SC; Sousa N; Salgado AJ Prog Neurobiol; 2017 Sep; 156():69-89. PubMed ID: 28457671 [TBL] [Abstract][Full Text] [Related]
10. Overlapping molecular signatures in Parkinson's patients' leukocytes before and after treatment and in mouse model brain regions. Soreq L; Bergman H; Israel Z; Soreq H CNS Neurol Disord Drug Targets; 2013 Dec; 12(8):1086-93. PubMed ID: 24040822 [TBL] [Abstract][Full Text] [Related]
11. Recent advances in dopaminergic strategies for the treatment of Parkinson's disease. Mao Q; Qin WZ; Zhang A; Ye N Acta Pharmacol Sin; 2020 Apr; 41(4):471-482. PubMed ID: 32112042 [TBL] [Abstract][Full Text] [Related]
17. Targeting delivery in Parkinson's disease. Newland B; Dunnett SB; Dowd E Drug Discov Today; 2016 Aug; 21(8):1313-20. PubMed ID: 27312875 [TBL] [Abstract][Full Text] [Related]
18. What's in the pipeline for the treatment of Parkinson's disease? Sommer DB; Stacy MA Expert Rev Neurother; 2008 Dec; 8(12):1829-39. PubMed ID: 19086879 [TBL] [Abstract][Full Text] [Related]
19. Biomarkers in Parkinson's disease: Advances and strategies. Delenclos M; Jones DR; McLean PJ; Uitti RJ Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1(Suppl 1):S106-10. PubMed ID: 26439946 [TBL] [Abstract][Full Text] [Related]